Halozyme Therapeutics - 48 Year Dividend History | HALO

Historical dividend payout and yield for Halozyme Therapeutics (HALO) since 1971. The current TTM dividend payout for Halozyme Therapeutics (HALO) as of June 17, 2019 is $0.00. The current dividend yield for Halozyme Therapeutics as of June 17, 2019 is 0.00%.
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $2.289B $0.152B
Halozyme Therapeutics, Inc. is a therapeutically driven, development stage biopharmaceutical company dedicated to developing and commercializing recombinant human enzymes for the infertility, ophthalmology, and oncology communities. The company's broad product development portfolio, including expected near- and long-term product offerings, is based on intellectual property covering the family of human enzymes known as hyaluronidases. The company's initial products are being developed to offer safer and purer alternatives toexisting slaughterhouse derived extracts that carry risks of pathogen contamination, immunogenicity, and toxicity. The commercialization of Halozyme's highly versatile enzyme technology within proven markets will enable the company to positively impact the quality of medicine.
Stock Name Country Market Cap PE Ratio
Amgen (AMGN) United States $107.397B 12.14
Gilead Sciences (GILD) United States $84.602B 10.27
Bio-Techne Corp (TECH) United States $7.890B 53.83